While trichomoniasis is the most common curable sexually transmitted disease (STD) in the United States,1 reports of metronidazole-resistant trichomoniasis are increasing. New evidence indicates that tinidazole (Tindamax, Presutti Laboratories, Rolling Meadows, IL), recently introduced in the United States, is an effective therapy for metronidazole-resistant trichomoniasis and is well tolerated even at high doses.